Jump to main content
Jump to site search

Issue 6, 2015
Previous Article Next Article

Cationic phosphorus dendrimers and therapy for Alzheimer's disease

Author affiliations


Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by the aggregation of extracellular β-amyloid and the intracellular microtubule-associated protein Tau. Neurodegeneration is associated inter alia with the activation of microglial cells, neuroinflammation, oxidative stress, and diminished transduction of impulses in cholinergic neurons. Current pharmacotherapy for AD is based mainly on modulation of acetylcholine hydrolysis, administration of non-steroidal anti-inflammatory drugs and antioxidants. Novel drugs with antiamyloidic properties are currently being sought. Cationic phosphorus dendrimers have been proven to modulate amyloidogenesis and stop the aggregation of Tau protein. An ideal drug for AD should demonstrate anti-inflammatory properties, inhibit acetylcholine hydrolysis, and have antioxidant capacity. Cationic phosphorus dendrimers (generation 3 and generation 4) show the foregoing properties. They inhibit acetylcholinesterase activity, can decrease the secretion of TNF-α, and have weak antioxidant effects. The results presented suggest that phosphorus dendrimers may be considered in the future as agents in AD therapy.

Graphical abstract: Cationic phosphorus dendrimers and therapy for Alzheimer's disease

Back to tab navigation

Publication details

The article was received on 04 Feb 2015, accepted on 04 Apr 2015 and first published on 08 Apr 2015

Article type: Paper
DOI: 10.1039/C5NJ00309A
Author version
Download author version (PDF)
Citation: New J. Chem., 2015,39, 4852-4859
  •   Request permissions

    Cationic phosphorus dendrimers and therapy for Alzheimer's disease

    T. Wasiak, M. Marcinkowska, I. Pieszynski, M. Zablocka, A. Caminade, J. Majoral and B. Klajnert-Maculewicz, New J. Chem., 2015, 39, 4852
    DOI: 10.1039/C5NJ00309A

Search articles by author